73 related articles for article (PubMed ID: 3247816)
1. Prognostic factors in refractory anemias.
Oguma S; Yoshida Y; Uchino H; Maekawa T
Nihon Ketsueki Gakkai Zasshi; 1988 Dec; 51(8):1412-8. PubMed ID: 3247816
[No Abstract] [Full Text] [Related]
2. Myelodysplastic syndromes: natural history and features of prognostic importance.
Mufti GJ; Galton DA
Clin Haematol; 1986 Nov; 15(4):953-71. PubMed ID: 3552350
[No Abstract] [Full Text] [Related]
3. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
Estey EH; Keating MJ; Dixon DO; Trujillo JM; McCredie KB; Freireich EJ
Hematol Pathol; 1987; 1(4):203-8. PubMed ID: 3504436
[TBL] [Abstract][Full Text] [Related]
4. Factors influencing leukemic transformation in refractory anemias with excess of blasts, with ringed sideroblasts, and without ringed sideroblasts.
Oguma S; Yoshida Y; Uchino H; Maekawa T
Cancer Res; 1986 Jul; 46(7):3698-700. PubMed ID: 3458528
[TBL] [Abstract][Full Text] [Related]
5. [Refractory anemia showing excess of blasts (BAEB) that transformed into acute myelogenous leukemia (AML-M2) with a t (?8;20) chromosomal abnormality].
Maekawa T; Fujii H; Shizumi Y; Ebisui S; Horishi M; Suyama Y; Miyoshi M; Horiike S
Gan No Rinsho; 1988 Dec; 34(15):2109-13. PubMed ID: 3230641
[TBL] [Abstract][Full Text] [Related]
6. Percentages of bone marrow blasts and chromosomal changes in patients with refractory anemia help to determine prognoses.
Iwabuchi A; Ohyashiki K; Ohyashiki JH; Kimura Y; Lin KY; Aizawa S; Nehashi Y; Miyazawa K; Yaguchi M; Toyama K
Int J Hematol; 1994 Oct; 60(3):207-13. PubMed ID: 7858240
[TBL] [Abstract][Full Text] [Related]
7. Factors influencing nonleukemic death in refractory anemia, refractory anemia with ring sideroblasts, and refractory anemia with excess of blasts.
Oguma S; Yoshida Y; Uchino H; Maekawa T
Cancer Res; 1987 Jul; 47(13):3599-602. PubMed ID: 3581090
[TBL] [Abstract][Full Text] [Related]
8. Clinical features of long-term survivors of refractory myelodysplastic anemias. A Japanese cooperative study.
Yoshida Y; Oguma S; Uchino H; Maekawa T; Nomura T
Leuk Res; 1992 Aug; 16(8):775-9. PubMed ID: 1528065
[TBL] [Abstract][Full Text] [Related]
9. [The concept of and countermeasures in refractory anemia].
Yoshida Y
Nihon Naika Gakkai Zasshi; 1990 May; 79(5):593-7. PubMed ID: 2199586
[No Abstract] [Full Text] [Related]
10. The myelodysplastic syndromes. Part I. What are they? Part II. Classification.
Galton DA
Scand J Haematol Suppl; 1986; 45():11-20. PubMed ID: 3515515
[No Abstract] [Full Text] [Related]
11. [Transmission ultrastructure in the study of acquired refractory anemias].
Woessner S; Lafuente R; Florensa L; Vilá RM; Sans-Sabrafen J
Sangre (Barc); 1986; 31(1):40-56. PubMed ID: 3458311
[No Abstract] [Full Text] [Related]
12. [Cutaneous leukemia in refractory anemia with an excess of blasts in transformation].
Mestre F; Pinazo I; Betlloch I; Mas JM; Galmes A; Buades J
Ann Dermatol Venereol; 1988; 115(12):1265-9. PubMed ID: 3071964
[No Abstract] [Full Text] [Related]
13. [Coexistence of Hodgkin's disease and myelodysplastic syndrome with late conversion to acute myeloblastic leukemia].
Woźny T
Wiad Lek; 1989 Feb; 42(3):170-2. PubMed ID: 2623860
[TBL] [Abstract][Full Text] [Related]
14. Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcome.
Knipp S; Strupp C; Gattermann N; Hildebrandt B; Schapira M; Giagounidis A; Aul C; Haas R; Germing U
Leuk Res; 2008 Jan; 32(1):33-7. PubMed ID: 17412418
[TBL] [Abstract][Full Text] [Related]
15. [Refractory anemia with excess of blasts in transformation induced by thorotrast].
Haruyama H; Fujita N; Shimazaki C; Nakanishi S; Sugishima K; Nakagawa M; Ijichi H; Taniwaki M; Kitamura T; Mori T
Rinsho Ketsueki; 1988 Jun; 29(6):840-4. PubMed ID: 3166495
[No Abstract] [Full Text] [Related]
16. [Factors influencing leukemic transformation in myelodysplastic syndrome].
Borbényi Z; Varga G; Bérczi M; Gurzó M
Orv Hetil; 1990 Jun; 131(23):1231-6, 1239-40. PubMed ID: 2199892
[TBL] [Abstract][Full Text] [Related]
17. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
Omine M; Yamauchi H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556
[TBL] [Abstract][Full Text] [Related]
18. A case of monocytic leukaemia cutis in a patient with myelodysplastic syndrome transforming to acute myeloid leukaemia.
Perez A; Kennedy C; Standen G; Oxley J
Clin Exp Dermatol; 2004 Sep; 29(5):497-8. PubMed ID: 15347335
[TBL] [Abstract][Full Text] [Related]
19. New system for assessing the prognosis of refractory anemia patients.
Matsuda A; Jinnai I; Yagasaki F; Kusumoto S; Murohashi I; Bessho M; Hirashima K; Honda S; Minamihisamatsu M; Fuchigami K; Matsuo T; Kuriyama K; Tomonaga M
Leukemia; 1999 Nov; 13(11):1727-34. PubMed ID: 10557045
[TBL] [Abstract][Full Text] [Related]
20. [Development and treatment of myelodysplastic syndrome].
Krafft T
Rev Med Suisse Romande; 1988 Jul; 108(7):571-2. PubMed ID: 3166181
[No Abstract] [Full Text] [Related]
[Next] [New Search]
